Baker Tilly Wealth Management LLC recently cut its stake in AbbVie Inc. by 3.5%, selling 169 shares in the second quarter. This downward adjustment, disclosed in the firm’s Form 13F filing, leaves the institutional investor with 4,602 shares.

AbbVie is set to acquire Gilgamesh Pharmaceuticals’ bretisilocin, a next-generation psychedelic compound with promising Phase 2 results for major depressive disorder. The treatment’s short-acting properties and robust clinical data highlight its potential to address critical gaps in current psychiatric therapies.